. 2017 Mar 30;18:112. doi: 10.1186/s12882-017-0519-4

Table 2.

Proteins differentiating between microalbuminuric and non-microalbuminuric groups

				Theoretical^a		MS		MS/MS
Spot No	Protein Name	SwissProt entry	Biological function^b	MW (kDa)	pI	Peptide count	Protein score	Peptide count	Total ion score	Spot intensity ratio^c	p^d
1	Kininogen-1	KNG1	blood coagulation, source of bradykinin	71912	6,34			5	184	0.110	<0,0001
2	Alpha-enolase	ENOA	glycolysis (step 9/10), cell growth, fibrinolysis	47139	7,01			4	106	0.076	<0,0001
3	Glyceraldehyde-3-phosphate dehydrogenase	G3P	glycolysis (step 6/10), nuclear regulatory functions, apoptosis	36030	8,57			2	57	0.018	<0,0001
4	Alpha-enolase	ENOA		47139	7,01	6	57	5	257	0.140	<0,0001
5	Glyceraldehyde-3-phosphate dehydrogenase	G3P		36030	8,57			1	70	0.091	<0,0001
6	Vesicular integral-membrane protein VIP36	LMAN2	intracellular protein trafficking (Golgi to ER)	40203	6,46			2	81	0.335	<0,001
7	Protein AMBP	AMBP	trypsin inhibitor	38974	5,95			1	35	0.331	<0,01
8	Fibrinogen alpha chain	FIBA	blood coagulation	94914	5,7			2	40	0.238	<0,001
9	Glutaminyl-peptide cyclotransferase	QPCT	N-terminal pyroglutamate formation	40851	6,12	8	67	4	161	0.165	<0,001
10	Glutaminyl-peptide cyclotransferase	QPCT		40851	6,12			3	99	0.190	<0,0001
11	Basement membrane-specific heparan sulphate proteoglycan core protein	PGBM	component of basement membrane, anti-angiogenesis	468501	6,06			5	347	0. 364	<0,001
12	Non-secretory ribonuclease	RNAS2	non-secretory ribonuclease	18342	9,1			5	391	0.162	<0,001
13	Multimerin-2	MMRN2	endothelial surface protein, anti-angiogenesis	104344	5,56			1	51	0.202	<0,01
14	Peptidoglycan recognition protein 1	PGRP1	pattern recognition, innate immunity	21717	8,92			2	122	0.366	<0,01
14	Phosphatidylethanolamine-binding protein 1	PEBP1	serine protease inhibitor, Raf kinase inhibitor	21044	7,01			1	58	0.366	<0,01
15	Inter-alpha-trypsin inhibitor heavy chain H4	ITIH4	immunomodulation (acute phase)	103293	6,51			2	46	0.406	<0,01
16	Secreted and transmembrane protein 1	SCTM1	T-cell co-stimulatory ligand	27022	7			2	93	0.219	<0,01
17	Secreted and transmembrane protein 1	SCTM1		27022	7			1	37	0.156	<0,001
18	Serum albumin	ALBU	major plasma protein	69321	5,92			2	82	1.9	<0,001
19	Serum albumin	ALBU		69321	5,92			2	63	4.4	<0,01
20	Ig lambda-2 chain C region	LAC2	immunoglobulin	11287	6.92			2	188	3.1	<0,0001
20	Ig kappa chain C region	IGKC	immunoglobulin	11602	5.58			1	44	3.1	<0,05
21	Zinc-alpha-2-glycoprotein	ZA2G	fatty acid binding	34237	5,71	10	54	2	196	3.8	<0,0001
22	Serotransferrin	TRFE	iron binding, cell proliferation	77000	6,81	23	119	3	193	2.8	<0,01
23	Ceruloplasmin	CERU	copper binding	122128	5,44			7	495	1.2	<0,0001
24	Serum albumin	ALBU		69321	5,92			4	150	3.9	<0,001
25	Serum albumin	ALBU		69321	5,92			2	83	3.9	<0,01
26	Serum albumin	ALBU		69321	5,92			2	113	5.0	<0.01
27	Mannan-binding lectin serine protease 2	MASP2	complement activation (lectin pathway)	75685	5,47			7	430	4.2	<0,001
28	Serum albumin	ALBU		69321	5,92			4	95	5.6	<0,0001
29	Serum albumin	ALBU		69321	5,92			2	46	8.5	<0,0001
30	Alpha-1-acid glycoprotein 1	A1AG1	immunomodulation (acute phase)	23497	4,93			2	82	4.1	<0,001
31	Serotransferrin	TRFE		77000	6,81	22	111	4	248	11.6	<0,0001
32	Serotransferrin	TRFE		77000	6,81	23	147	8	268	3.8	<0,0001
33	Serotransferrin	TRFE		77000	6,81	26	151	5	396	5.5	NS

^aTheoretical MW and pI were retrieved from SwissProt database and correspond to intact proteins, irrespective of post-translational modifications

^bDescriptions of proteins’ biological functions were extracted from SwissProt database

^cSpot intensity ratios are calculated from group averages and expressed relative to non-microalbuminuric group

^dMedian spot volumes were compared between the two groups using Mann–Whitney rank sum test